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Introduction: Ten viral genotypes (A-J) distributed in all continents have been described for hepatitis 
B virus (HBV). One of the methodologies for determining the viral genotype is the restriction fragment 
length polymorphism (RFLP) technique, a simple and relatively inexpensive method, albeit with 
some limitations.
Objective: The initial objective of the project was to identify the HBV genotypes by RFLP in serum 
samples obtained from patients and blood donors. However, due to the discrepancies of RFLP patterns 
it was also necessary to perform phylogenetic genotyping and in silico analysis of HBV sequences.
Materials and methods: We obtained 56 serum samples. DNA extraction was followed by PCR 
amplification of a fragment of HBV ORF S. We analyzed PCR products by RFLP with AlwI, BsrI, CfrI, 
HpaII and StyI, and we sequenced some. We compared the patterns obtained with those in previous 
reports. We also performed RFLP analysis in silico since we found differences between the patterns 
expected and those obtained
Results: We identified genotypes A and F, subgenotype F3, in the samples. This result is in agreement 
with those of previous studies carried out in Colombia; indeed, subgenotype F3 is the most frequent in 
the Andean region of the country, while genotype A is the most frequent HBV genotype in the western 
region (department of Chocó). Based on the in silico analysis of 229 HBV sequences from GenBank 
and 11 sequences of this study, we identified the RLFP pattern for genotype F, subgenotype F3, and we 
described some modifications of genotype A RFLP patterns. 
Conclusions: We identified the single nucleotide polymorphism pattern for genotype F, subgenotype 
F3, by in silico analysis and sequencing. Further robust in silico analyses are necessary to validate the 
RFLP patterns of HBV genotype and subgenotypes.
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Análisis de genotipos del virus de la hepatitis B mediante el análisis de polimorfismos de 
longitud de fragmentos de restricción 
Introducción. Se han descrito diez genotipos (A-J) del virus de la hepatitis B (HBV) que están 
distribuidos en todos los continentes. Una de las técnicas utilizadas para determinar el genotipo 
viral es el análisis del polimorfismo de longitud de los fragmentos de restricción, un método simple y 
económico, pero con algunas limitaciones.
Objetivo. El objetivo inicial del estudio fue identificar el genotipo del HBV mediante RFLP en muestras 
de suero obtenidas de pacientes y donantes de sangre. Sin embargo, por las discrepancias observadas 
en los patrones de RFLP fue necesario realizar análisis filogenéticos y un análisis in silico de secuencias 
del HBV.
Materiales y métodos. Se obtuvieron 56 muestras de suero. Tras la extracción de ADN, se amplificó 
un fragmento del ORF S del HBV mediante reacción en cadena de la polimerasa, cuyos productos 
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se analizaron por RFLP con las enzimas AlwI, BsrI, CfrI, HpaII y StyI, y algunos se secuenciaron. Los 
patrones obtenidos se compararon con los reportados previamente. Se efectuó un análisis in silico de 
RFLP en consideración de las diferencias entre los patrones esperados y los observados. 
Resultados. Se identificaron los genotipos A y F, subgenotipo F3, en las muestras. Este resultado 
coincide con lo descrito en estudios previos en los que se ha demostrado que el genotipo F, subgenotipo 
F3, es prevalente en la población de la región andina del país, en tanto que el genotipo A predomina 
en el occidente (departamento del Chocó). Con base en el análisis in silico de 229 secuencias virales 
obtenidas del GenBank y las 11 secuencias de este estudio, se caracterizó un nuevo patrón de RFLP 
específico para el genotipo F, subgenotipo F3, y se describieron algunas modificaciones en el patrón 
de RFLP del genotipo A, subgenotipo A1.
Conclusiones. Se caracterizó el patrón de genotipificación del genotipo F, subgenotipo F3, del HBV 
mediante RFLP, análisis in silico y secuenciación. Se requieren nuevos análisis in silico con un número 
mayor de secuencias para validar los patrones de RFLP de los genotipos y subgenotipos del VHB.
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Hepatitis B virus (HBV) infection is a worldwide 
public health problem (1). Hepatitis B virus 
belongs to the Hepadnaviridae family, genus 
Orthohepadnavirus and has a partially double-
stranded circular DNA genome of 3.2 kb, with four 
overlapped open reading frames (ORF): S, precore/
core, polymerase and X (2-4).
Hepatitis B virus has been classified as having 10 
genotypes (A-J), and subgenotypes have been 
reported for four of these, i.e., A-D, F and I (5-10). 
The geographical distribution of HBV genotypes is 
as follows: A (subgenotypes A1-A6) in Asia, Africa, 
Europe and America; B (subgenotypes B1-B9) in 
Asia, Oceania and Canada; C (subgenotypes C1-
C16), prevalent in Asia and Oceania. Genotype D 
(subgenotypes D1-D9) has a global distribution, 
and so does genotype A; however, it circulates 
mostly in Europe, the Middle East, North Asia, 
Australia and the USA. Genotype E is found in 
West and Central Africa, although a few cases have 
also been reported in Europe (11) and Colombia 
(12). Genotype G is found in France, Germany, 
Japan, USA and Africa. The two newly identified and 
putative genotypes I (I1-I2) and J were described in 
samples obtained from patients from Laos (13) and 
Japan (14), respectively. Genotypes F and H are 
exclusive to America: Genotype F (subgenotypes 
F1-F4) is found throughout the Americas, from 
Alaska to Argentina, while genotype H is found in 
Central America and southern US (7-9,15-18).
Colombia is a country of low-intermediate preva-
lence for hepatitis B infection (19). According to 
the Instituto Nacional de Salud, 2,258 cases of 
hepatitis B were reported in 2014 (incidence: 
4.73/100,000); however, the departments of 
Amazonas, Norte de Santander, Guainía, Guaviare 
and Chocó showed higher incidence rates of HBV 
infection (20). 
The gold standard technique for HBV genotyping 
is phylogenetic analysis (21); however, this 
technique is expensive and time-consuming, 
it requires technology resources and trained 
personnel that are not widely available in public 
health laboratories. Alternative techniques that 
have been used for HBV genotyping include 
microarrays (DNA-chips) (22), restriction fragment 
length polymorphism (RFLP) (23), multiplex PCR 
(24) and hybridization with genotype-specific probes 
(INNO-LiPA) (25,26).
Various RFLP protocols for HBV genotyping 
have been described, most of them based 
on the amplification and restriction of ORF S 
sequences (23,27-29). The RFLP method is used 
in genotyping studies because it is a simple and 
relatively inexpensive method to determine the 
HBV genotype, particularly for large-scale analyses 
(30-32). 
In the present study, we used RFLP to characterize 
HBV strains obtained from Colombian patients 
and blood donors. As we found inconsistencies 
with previously published RFLP patterns for A 
and F genotypes, we carried out an in silico RLFP 
analysis to clarify these results. We report here the 
new restriction pattern for genotype F, subgenotype 
F3, and some modifications of genotype A, sub-
genotype A1, pattern.
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Materials and methods
Samples
We obtained 56 serum samples from patients, 
blood donors and asymptomatic individuals with 
risk factors. We included 45 samples from blood 
donors positive for hepatitis B surface antigen 
(HBsAg) and anti-HBV core antibodies (anti-HBc). 
The samples were sent in 2007 by four different 
blood banks to the Laboratorio de Salud Pública 
de Antioquia for confirmatory tests. Nine samples 
from patients with clinical diagnosis of viral hepatitis 
(HBsAg+ and anti-HBc+) were obtained during 2008 
and 2009 from primary health units in Medellín. 
We also included two serum samples obtained in 
2009 from asymptomatic patients with risk factors 
for HBV infection from the cities of Quibdó and 
Apartadó (western Colombia), positive for HBsAg 
by rapid test (One Step HBsAg Rapid Test Kit, 
Intec, China) and by ELISA (HBsAg microparticle 
enzyme immunoassay, Abbot, USA).
Samples were stored at -70°C prior to DNA 
extraction, which was done no later than six months 
after serum collection.
All participating patients and blood donors signed 
the informed consent and donation forms. The 
ethics committees of Universidad de Antioquia-
SIU and the Fundacion Antioqueña de Infectología 
approved the studies.
HBV DNA detection
We extracted total DNA from 175 μl of each serum 
sample using TRIzol Reagent (Invitrogen, USA). 
We amplified a fragment of the HBV ORF S (585 
nt) by hemi-nested or nested polymerase chain 
reaction (PCR), using primers PresS2, S1R, Ys1 
and YS2 (29).
For the nested PCR, we performed both amplifi-
cation rounds using two units of Taq polymerase 
(Fermentas, USA), 2.5 mM of MgCl2, 5 μM of dNTP 
(Promega, USA) and 0.5 mM of primers S1R and 
PrsS2 for the first PCR, and of YS1 and YS2 for the 
second one. The thermal cycling conditions were 
as follows: An initial 3 min step at 95°C followed by 
40 cycles of amplification at 94°C for 45 sec, 53°C 
for 1 min, 72°C for 1 min, and a final step at 72°C 
for 5 min. 
Both amplification rounds of the semi-nested PCR 
were carried out using two units of Taq polymerase 
(Fermentas, USA), 2mM MgCl2, 10 μM dNTPs 
(Promega, USA), and 0.5 mM primers YS1 and 
SR1 for the first PCR and YS1 and YS2 for the 
second PCR. The thermal cycling conditions were: 
an initial 3 min step at 95°C, followed by 40 cycles 
of 94°C for 1 min, 53°C for 40 sec and 72°C for 1 
min, and a last step at 72°C for 5 min. We visualized 
PCR products in a 2% agarose gel stained with 
ethidium bromide.
Hepatitis B virus genotyping
We purified PCR products using standard Exo 
Sap-IT (USB, Staufen, Germany). We analyzed 
the nucleotide sequences of PCR products in 
both senses by automated dideoxy-sequencing 
(Macrogen Inc. Seoul, Rep. of Korea).
The sequences obtained were aligned with 118 
HBV sequences for ORF S available in GenBank 
using the Clustal W Multiple Alignment application 
contained in BioEdit 7.0.5.3 (33). Phylogenetic 
analysis was conducted using MEGA, version 
5.0 (34) applying the neighbor-joining method 
with genetic distances evaluated with Kimura 2 
parameters corrections, maximum parsimony and 
maximum likelihood. We statistically evaluated the 
reliability of the trees by bootstrap analysis with 
1,000 replicates.
PCR products digestion was done in independent 
reactions with each of these restriction enzymes: 
AlwI, BsrI, HpaII, StyI (Biolabs, USA) or CfrI 
(Fermentas, USA). Enzyme AlwI was used in 
this analysis instead of DpnI or Sau3AI enzymes 
used in previous studies (33). The AlwI restriction 
site is GGATC while the restriction site for DpnI 
and Sau3AI is GATC. However, for the definition 
of the new restriction patterns described in the 
present study we did not consider the differences 
between previous reports and our findings using 
this enzyme.
We visualized digested products in 3% agarose 
gels stained with ethidium bromide. 
The viral genotype was determined by comparing 
the obtained restriction pattern with the patterns 
previously reported by Zeng, et al. (29) and 
Venegas, et al. (30). 
In silico RFLP and pairwise sequence analysis
We conducted an in silico RLFP analysis after we 
found that the patterns obtained did not match 
those in previous reports. For this analysis, we 
obtained sequences of genotypes A-H from the 
GenBank database based on the geographical 
origin. We selected two hundred and twenty-nine 
sequences of HBV ORF S for this analysis. The 
selection criterion was the availability of complete 
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HBV genome sequences at GenBank. Furthermore, 
we selected sequences from studies carried out 
with samples from different locations or at the same 
location but in a different period. Where complete 
HBV genome sequences were not available, then 
those of ORF S were included in the analysis.
The region between 203 nt and 767 nt (with 
sequence NC003977 as reference) was aligned 
and analyzed to determine the expected pattern 
obtained after digestion with AlwI, BsrI, CfrI, HpaII 
and StyI restriction enzymes using the software 
BioEdit 7.0.9.0 (Ibis biosciences, Canada).
Results
HBV molecular detection and genotyping
We amplified a fragment of the HBV ORF S by PCR 
in 17/56 serum samples: 6/45 (13.3%) from blood 
donors, 9/9 from patients with clinical diagnosis 
of viral hepatitis, and 2/2 from asymptomatic 
individuals with risk factors.
The low proportion of samples from blood donors 
with HBV DNA amplification (13.3%) could be 
due to the DNA extraction method (Trizol) and its 
efficiency for low viral load samples. 
We conducted RFLP analysis for these 17 samples. 
These analyses showed three different restriction 
patterns (figure 1, patterns 1-3); nine samples 
showed pattern 1, one showed pattern 2, and 
seven, showed pattern 3. None of them was similar 
to the previously reported patterns (29,30).
Patterns 1 and 2 as reported by Zeng, et al. and 
Venegas, et al. (29,30) were quite similar to that of 
genotype A (figure 2, panel 1); however, restriction 
with AlwI generated only one fragment instead of 
three in the study samples (figure 1). 
On the other hand, pattern 3 was comparable 
with the expected result for genotype F (figure 
2, panel 3), except for the restriction with StyI 
enzyme resulting in two fragments in the samples 
rather than none, as seen in the pattern previously 
described.
Sequencing and phylogenetic analysis
We obtained the ORF S sequence from 11 serum 
samples previously analyzed by RFLP. No serum 
samples from blood donors remained for the phy-
logenetic analysis. We aligned the 11 sequences 
with 118 sequences of HBV selected from Gen 
Bank. The phylogenetic relationships of sequences 
were similar using different methodologies. Figure 
3 shows a representative phylogenetic tree. 
The phylogenetic analysis showed that 8/11 sam-
ples (72.7%) clustered with genotype A sequences, 
while the remaining three sequences (27.3%) 
clustered with genotype F (figure 3).
In silico analysis
In order to detect polymorphisms that could 
modify the RFLP patterns, we analyzed 229 HBV 
sequences available from GenBank in silico. 
Table 1 summarizes the variations in the sites 
recognized by the restriction enzymes used on 
the RFLP protocol.
The in silico analysis demonstrated that sequences 
corresponding to HBV genotype A (subgenotypes 
A2, A3, A4), genotype B (subgenotype B1), 
genotype D (subgenotypes D1, D2 and D4), 
and genotypes C, G and H showed identical 
patterns to those previously described by Zeng, 
et al. (29). On the other hand, the sequences 
corresponding to genotype A, subgenotype A1, 
previously described as pattern A3 by Zeng, et 
al., and to genotype B (subgenotypes B2 to B4), 
genotype D (subgenotypes D1 to D3), genotype F 
(subgenotypes F1 to F4), and genotype E exhibited 
variations on the restriction patterns (table 1). 
Two restriction sites in the sequences belonging 
to subgenotype A1 were found to be absent in 
5/9 sequences for AlwI (nt 291) and in 6/9 for BsrI 
(nt 501). Moreover, we identified four additional 
restriction sites for subgenotype A1: AlwI (nt 481) in 
6/9 sequences, BsrI (nt 757) in 4/9 sequences, StyI 
(nt 757) in 2/9 sequences and BsrI (nt 366) in 1/9 
sequences. We found variations in subgenotypes 
A2, A3 and A4, but only in 1-2 of the analyzed 
sequences, so we did not consider them significant 
(table 1, marked with asterisks).
Regarding subgenotype F3, 15 of the 25 sequences 
exhibited an additional restriction site for StyI (nt 
453), with two bands (334 and 251 bp) instead of 
1 2 3Hpall Bsrl Styl Cfrl Alwl Hpall Bsrl Styl Cfrl Alwl Hpall Bsrl Styl Cfrl Alwl
500
100
500
100
500
100
Figure 1. RFLP patterns of HBV. The PCR product of HBV S 
ORF digestion was done with AlwI, BsrI, CfrI, HpaII and StyI 
restriction enzymes and visualized in an agarose gel stained 
with ethidium bromide. All patterns are presented with a 100-bp 
ladder marker. 
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one (585 bp). This new restriction site could explain 
the results of the RFLP assays (figure 1, pattern 3) 
and would be useful in differentiating F3 from the 
other F subgenotypes.
Discussion
This study describes the HBV genotypes of serum 
samples obtained from Colombian patients and 
blood donors. We also report modifications of 
previously established RFLP patterns of HBV 
genotypes based on results obtained with serum 
samples and the in silico analysis of 229 HBV 
ORF S sequences.
We report a specific RFLP pattern for the F3 
subgenotype confirmed by sequencing and in 
silico analysis. Additionally, we characterized the 
pattern of genotype A sequences, subgenotype 
A1, previously reported by Zeng, et al., as pattern 
A3 (29) in a study conducted in 2004 where the 
authors described four patterns for genotype A; 
however, these are not strictly correlated with 
the subgenotypes A1, A2, A3, A4, considering 
the limited number of HBV sequences available 
before 2004. Moreover, the patterns A3 and 
A4 were identified using one sequence in each 
case (29).
RFLP is a good technique for viral genotyping 
because of its simplicity and low cost; however, 
there are some disadvantages such as the fact that 
it has to be done on a highly conserved sequence 
of 6-8 nucleotides and that mutations at the 
recognition site of the restriction enzymes could 
alter genotype characterization. It is important to 
take into account the genetic variability of HBV 
when identifying the polymorphisms that modify 
RFLP patterns present at each restriction enzyme 
recognition site. Nevertheless, RFLP continues to 
be used for HBV genotyping (32,35,36).
In our study, RFLP genotyping was based on 
the method described by Zeng, et al. (29). Since 
then, two new genotypes (13,37), and several new 
subgenotypes for genotypes A-D and F (38-42) 
have been described. The current classification by 
RFLP can now be re-evaluated taking into account 
this new data.
In our case, we analyzed each sample with the 
five restriction enzymes previously described 
in independent reactions. This differs from the 
methodology used in other studies, where a flow-
chart for restriction is followed for RFLP genotyping 
(29,30). The patterns we obtained were different to 
those previously reported, which led us to propose 
an in silico RFLP analysis of a large number of 
sequences for genotypes A to H. We identified a 
new specific RFLP pattern for the F3 subgeno-
type confirmed by sequencing and phylogenetic 
analysis, as well as some modifications of the 
subgenotype A1 pattern. 
We identified eight of the ten samples analyzed 
by RFLP that showed restriction patterns 1 or 2 
(figure 1) as genotype A by phylogenetic analysis 
(figure 3). On the other hand, we sequenced 
and identified three of seven samples showing 
restriction pattern 3 as genotype F. The new StyI 
restriction site at nt453 was present in these three 
sequences, as shown in figure 1; given that this 
site was found in a representative number of F3 
sequences in the in silico analysis (15/25), but only 
one of the six F4 sequences and none of the ten 
1 2 3 4
Hpall Bsrl
A2  -  A3  -  A4
500bp
F1  -  F2  -  F4Subgenotype A1 Subgenotype F3
Styl Cfrl Alwl Hpall Bsrl Styl Cfrl Alwl Hpall Bsrl Styl Cfrl Alwl Hpall Bsrl Styl Cfrl Alwl
Figure 2. Schematic representation of RFLP patterns for HBV genotypes A and F. Panels 1 and 3 represent the patterns for 
genotypes A and F described previously, panel 2 shows the restriction pattern for subgenotype A1 and panel 4 the new pattern for 
subgenotype F3. All patterns are presented with a 100-bp molecular marker. 
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sequences analyzed for F1 and F2, these results 
suggest that the samples under study belong to 
subgenotype F3.
Given the results for the restriction pattern and 
the phylogenetic analysis, the genotypes of six 
samples analyzed by RFLP but not sequenced 
were determined based solely on the restriction 
pattern: Four of these samples showed pattern 
3 and were classified as genotype F3, while 
the remaining two showed pattern 1 and were 
classified as genotype A (table 2, figure 2).
Genotype F, considered to be restricted to the 
Americas (8), has been described mainly in 
Colombian populations from the Andean region 
and Amerindians in the southeast of the country; 
indeed, subgenotype F3 is the most frequent 
in the former and F1b in the latter (Amazonas 
department). Meanwhile, genotype A has been 
very frequently found in western Colombia, where 
most of the population is of African descent (43-
51). Additionally, an F3/A1 recombinant strain 
(44) and some strains of genotype E have been 
reported in an Afro-Colombian community (12). 
HBV genotype distribution has a complex pattern 
in Colombia, which has not been described ade-
quately because of the limited amount of HBV 
genotyping data available. In this sense, it is 
especially important to conduct studies in northern 
and eastern Colombia.
The phylogenetic analysis of the sequences 
included in this study showed that 72.7% (8/11) 
were genotype A, which represents a high propor-
tion compared to previous reports of HBV genotypes 
in the country. It is important to note that we had 
no information about the ethnic background of 
the participants in this study. Genotype A has 
also been reported in a high proportion in studies 
conducted in the cities of Quibdó and Apartadó, 
where the population is predominantly of African 
descent (44,49). According to the general census 
of 2005, around 11% of the population in the 
department of Antioquia identify themselves as 
black, mulato (mixed black and white ancestry), 
Afro-Colombian or otherwise of African descent, 
while in Chocó this proportion is 82.12% (52). 
Genotype A might have been introduced by slaves 
brought to the country during the Spanish colonial 
period, as has been reported for other South 
American countries (12,53,54).
A limitation of the present study was the low 
proportion of positive serum samples from HBsAg 
and anti-HBc positive blood donors (13.3%). The 
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Figure 3. Unrooted parsimony phylogenetic trees of the HBV 
ORF S region. Colombian sequences obtained in this study 
(n=11) were compared with worldwide reference strains. 
Bootstrap: 1,000.
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Table 1. In silico analysis of RFLP patterns of HBV ORF S sequences. HpaII, AlwI, CfrI, BsrI and StyI restriction sites in the S ORF 
fragment in each genotype and subgenotype analyzed
Genotype/
Sub-genotype
Number of HBV sequences with the restriction site
Number of 
sequences analyzed
290
HpaII
291
AlwI
300
CfrI
326
BsrI
366
BsrI
453
StyI
481
AlwI
495
AlwI
501
BsrI
505
HpaII
674
BsrI
704
HpaII
727
BsrI
757
BsrI
A AlwI CfrI AlwI BsrI
A1   9 4   9 * *   6   9 * 4
A2   9 8   9 *   9 8 *
A3   9 7   9 *   8 9
A4   8 6   8 * *   8 6 *
B CfrI BsrI AlwI
B1 13 13 13 13 *
B2 13 13 13 13 12
B3   4   4   4   4  *2
B4   6   6   6   6
C CfrI StyI
C1 14 14 13
C2 12 12   9
C3   6   6   5 * *
C4   2 *   2 *
D CfrI AlwI
D1 12 12 12 *
D2 10 10 10
D3 11 11 * 10 11
D4   8   8 *   8 * *
E CfrI BsrI AlwI BsrI HpaII
E 10 10 1 10   9 8 *
F HpaII CfrI AlwI
F1 10   8 10 10 10
F2 10   9 10 10 10
F3 25 22 25 15 22 25 *
F4   6   6   6 * *   6
G AlwI AlwI BsrI
G   9  *2   9   9   9 *
H HpaII CfrI AlwI
H 12 12 12 12
The new informative restriction sites appear in bold rectangles and those found with only one or two sequences are marked with asterisks (*). Positions 
of the restriction sites are displayed in the first row and are based on the sequence NC_003977.
Table 2. HBV genotyping by RFLP and phylogenetic analysis of serum samples obtained from patients and blood donors
Code Sample Genotype by RFLP Genotype by phylogenetic 
analysis
Pattern Proposed genotype
colvh1 Patients with clinical diagnosis 
of viral hepatitis
2 A A
colvh2 1 A A
colvh3 1 A A
colvh4 1 A A
colvh5 3 F F
colvh6 1 A A
colvh7 1 A A
colvh8 1 A A
colvh9 1 A A
AP169 Asymptomatic individuals with 
HBV risk factors
3 F F
AP533 3 F F
colbd1 Blood donors 3 F ND
colbd2 3 F ND
colbd3 3 F ND
colbd4 1 A ND
colbd5 3 F ND
colbd6 1 A ND
ND: Not determined
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efficiency of DNA extraction and the detection limit 
of the in-house semi-nested and nested PCRs 
could have had a negative impact on HBV DNA 
detection. HBV DNA amplification in samples from 
HBsAg+ blood donors was probably influenced by 
the low viral load, as described previously; these 
cases could correspond to inactive carriers (IC) 
of HBV infection, characterized by normal alanine 
aminotransferase level, HBeAg negativity and viral 
load ≤2,000 UI/ml (55). Additionally, Gupta, et al. 
demonstrated a significant correlation between 
HBsAg levels and DNA HBV in samples of >2,000 
UI/ml but not in those of ≤2,000 UI/ml using real-
time PCR (56). In another study, the authors 
evaluated in-house semi-nested PCR for HBV DNA 
detection performance in serum samples reactive 
for HBsAg comparing it with the performance of a 
commercial method (Cobas Amplicor HBV Monitor 
Assay). The HBV DNA detection by in-house semi-
nested PCR showed a concordance of 67.8% 
with the commercial technique. The authors thus 
concluded that the former technique showed an 
adequate concordance with some limitations, being 
a good method in low-resource settings (57).
In conclusion, we identified a new restriction pattern 
specific for subgenotype F3, and provided an in 
silico analysis of informative restriction sites for 
genotypes A-H that complements work which has 
been published before. Genotypes F and A were 
identified in the samples by RFLP and phylogenetic 
analysis according to previous genotyping studies 
in Colombia. A more robust in silico analysis (i.e., 
one including more sequences) of the restriction 
patterns for HBV genotypes and subgenotypes 
could validate our findings, making HBV genotyping 
by RFLP more reliable.
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